Citations

Showing 10 of 108083 citations.

SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19
Afshar, Zeinab Mohseni , Karim, Bardia , Anaraki, Shiva Rahimipour , Hosseinzadeh, Rezvan , Pireivatlou, Elaheh Sanjari, Hosseinzadeh, Dariush , Miri, Seyed Rouhollah , Barary, Mohammad , Ebrahimpour, Soheil , Sullman, Mark J M , Barary, Mohammad , Pirzaman, Ali Tavakoli , Babazadeh, Arefeh , Sio, Terence T. , Sullman, Mark J. M.

Mayo Clinic

Diagnostics | February 3, 2023 | Volume: 13 | Issue: 3 | Pages: 559

10.3390/diagnostics13030559 | PMID 36766664 Get It

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there have been multiple peaks of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus virus 2) infection, mainly due to the emergence of new variants, each with a new set of mutations in the viral genome, which have led to changes in the pathogenicity, transmissibility, and morbidity. The Omicron variant is the most recent variant of concern (VOC) to emerge and was recognized by the World Health Organization (WHO) on 26 November 2021. The Omicron lineage is phylogenetically distinct from earlier variants, including the previously dominant Delta SARS-CoV-2 variant. The reverse transcription–polymerase chain reaction (RT–PCR) test, rapid antigen assays, and chest computed tomography (CT) scans can help diagnose the Omicron variant. Furthermore, many agents are expected to have therapeutic benefits for those infected with the Omicron variant, including TriSb92, molnupiravir, nirmatrelvir, and their combination, corticosteroids, and interleukin-6 (IL-6) receptor blockers. Despite being milder than previous variants, the Omicron variant threatens many lives, particularly among the unvaccinated, due to its higher transmissibility, pathogenicity, and infectivity. Mounting evidence has reported the most common clinical manifestations of the Omicron variant to be fever, runny nose, sore throat, severe headache, and fatigue. This review summarizes the essential features of the Omicron variant, including its history, genome, transmissibility, clinical manifestations, diagnosis, management, and the effectiveness of existing vaccines against this VOC.
Unraveling multilayered extracellular vesicles: Speculation on cause
Broad, Kelly , Walker, Sierra A. , Davidovich, Irina, Witwer, Kenneth W. , Wolfram, Joy , Wolfram, Joy , Witwer, Kenneth W , Talmon, Yeshayahu

Mayo Clinic

Journal of Extracellular Vesicles | February 3, 2023 | Volume: 12 | Issue: 2 | Pages: No page available

10.1002/jev2.12309 | PMID 36732941 Get It

AbstractExtracellular vesicles (EVs) are cell‐released, heterogenous nanoparticles that play important roles in (patho)physiological processes through intercellular communication. EVs are often depicted as having a single lipid bilayer, but many studies have demonstrated the existence of multilayered EVs. There has been minimal inquiry into differences between unilamellar and multilamellar EVs in terms of biogenesis mechanisms and functional effects. This commentary speculates on potential causes and roles of multilamellar EVs and serves as a call to action for the research community to unravel the complex layers of EVs.
Preserving the Membrane Lung: An Ongoing ECMO Challenge
Wieruszewski, Patrick M. , Neal, James R. , Nabzdyk, Christoph S. , Seelhammer, Troy G. , Nabzdyk, Christoph G. S., Nabzdyk, Christoph , Wieruszewski, Patrick M

Mayo Clinic

ASAIO Journal | February 2, 2023 | Volume: 69 | Issue: 4 | Pages: e165-e165

10.1097/mat.0000000000001827 | PMID 36730912 Get It

Updates in diagnosis and management of paediatric mastocytosis
Tiano, Rasa, Krase, Ifat Z , Sacco, Keith

Mayo Clinic

Current Opinion in Allergy & Clinical Immunology | February 2, 2023 | Volume: 23 | Issue: 2 | Pages: 158-163

10.1097/aci.0000000000000869 | PMID 36730855 Get It

Purpose of review Paediatric mastocytosis is a rare clonal disorder characterized by the overproduction and organ infiltration of mast cells. Symptoms are due to mast cell mediator release. Cutaneous mastocytosis is the most common presentation in children with systemic disease being rare. Our aim is to provide a practical guideline in differentiating subtypes of paediatric mastocytosis while providing actionable recommendations on diagnosis, clinical management, follow-up and prognosis. Recent findings Longitudinal cohort studies of paediatric cutaneous mastocytosis have shown spontaneous remission with favourable prognosis. Hereditary alpha-tryptasemia may coexist with mastocytosis; thus, screening for this disorder is recommended. There is an emerging role for serum tryptase in asthma endotyping and potential for using therapeutic tryptase inhibitors. Summary Morbidity in paediatric mastocytosis typically arises from symptoms secondary to mast cell mediator release. Prognosis for nonaggressive disease is typically favourable; however, risks for anaphylaxis and psychosocial morbidity may be underestimated. Symptomatic management and anticipatory guidance may help support patients and families throughout the disease course.
Interventricular-Septal Output While Supported on Left Ventricular Assist Device Therapy
Inglis, Sara S. , Villavicencio, Mauricio T., Spencer, Philip J. , Schettle, Sarah , Stulak, John M., Clavell, Alfredo L. , Kushwaha, Sudhir S. , Rosenbaum, Andrew , Schettle, Sarah D., Rosenbaum, Andrew N , Inglis, Sara S , Villavicencio, Mauricio A. , Behfar, Atta

Mayo Clinic

ASAIO Journal | February 2, 2023 | Volume: 69 | Issue: 5 | Pages: 424-428

10.1097/mat.0000000000001851 | PMID 36730725 Get It

The effects of left ventricular unloading on septal function in patients with left ventricular assist devices (LVADs) have not been well characterized in vivo. The purpose of this study was to evaluate the relationship between markers of septal function with echocardiography in relationship to RV dysfunction and late RV failure after LVAD implantation. A retrospective study was conducted of patients supported on centrifugal-flow LVADs implanted over a 10-year period. Echocardiographic data were collected pre-operatively and up to 2 years after implantation. Interventricular septum (IVS) measurements were taken at end-systole and end-diastole. Interventricular-septal output (ISO) was calculated using the formula: (IVSs–IVSd)×heart rate. A total of 110 patients were included. An immediate and sustained reduction in both lateral annulus systolic velocity (RVS’) and TAPSE were observed after implant (p < 0.0001). However, ISO gradually decreased over time (p < 0.0001). While ISO was not predictive of late RV failure, a decrease in ISO by 25% or greater from pre-implant to hospital discharge was associated with late RV failure (OR 4.8; 95% CI, 1.4–16.5; p = 0.012) even after adjusting for relevant clinical variables (p ≤ 0.01 for each model). RV function is known to be influenced by mechanical ventricular interdependence and we demonstrate that measurement of ISO may be a useful marker in assessing RV dysfunction and predicting RV failure in patients following LVAD implantation.
Management of Anticoagulation/Antiplatelet Medication and Venous Thromboembolism Prophylaxis in Elective Spine Surgery: Concise Clinical Recommendations Based on a Modified Delphi Process
Berven, Sigurd, Streiff, Michael B. , Buchanan, Ian A. , Ha, Alex , Bonfield, Christopher M. , Buchholz, Avery L., Burch, Shane , Devin, Clinton J. , Dimar, John R. , Good, Christopher R. , Lombardi, Joseph M. , Mandigo, Christopher E. , Bydon, Mohamad , Oppenlander, Mark E., Poulter, Gregory T., Shah, Suken A. , Singh, Kern , Than, Khoi D. , Spyropoulos, Alex C. , Kaatz, Scott , Schutzer, Richard, Wang, Tina Z. , Mazique, Derek C., Lenke, Lawrence G. , Lehman, Ronald A. , Zuckerman, Scott L. , Kerolus, Mena G. , Buchowski, Jacob M. , Gum, Jeffrey L. , Kim, Han Jo , Kim, Jun , Polly, David W. , Jain, Amit

Mayo Clinic

Spine | February 2, 2023 | Volume: 48 | Issue: 5 | Pages: 301-309

10.1097/brs.0000000000004540 | PMID 36730667 Get It

Study Design. Delphi method. Objective. To gain consensus on the following questions: (1) When should anticoagulation/antiplatelet (AC/AP) medication be stopped before elective spine surgery?; (2) When should AC/AP medication be restarted after elective spine surgery?; (3) When, how, and in whom should venous thromboembolism (VTE) chemoprophylaxis be started after elective spinal surgery? Summary of Background Data. VTE can lead to significant morbidity after adult spine surgery, yet postoperative VTE prophylaxis practices vary considerably. The management of preoperative AC/AP medication is similarly heterogeneous. Materials and Methods. Delphi method of consensus development consisting of three rounds (January 26, 2021, to June 21, 2021). Results. Twenty-one spine surgeons were invited, and 20 surgeons completed all rounds of questioning. Consensus (>70% agreement) was achieved in 26/27 items. Group consensus stated that preoperative Direct Oral Anticoagulants should be stopped two days before surgery, warfarin stopped five days before surgery, and all remaining AC/AP medication and aspirin should be stopped seven days before surgery. For restarting AC/AP medication postoperatively, consensus was achieved for low-risk/medium-risk/high-risk patients in 5/5 risk factors (VTE history/cardiac/ambulation status/anterior approach/operation). The low/medium/high thresholds were POD7/POD5/POD2, respectively. For VTE chemoprophylaxis, consensus was achieved for low-risk/medium-risk/high-risk patients in 12/13 risk factors (age/BMI/VTE history/cardiac/cancer/hormone therapy/operation/anterior approach/staged separate days/staged same days/operative time/transfusion). The one area that did not gain consensus was same-day staged surgery. The low-threshold/medium-threshold/high-threshold ranges were postoperative day 5 (POD5) or none/POD3-4/POD1-2, respectively. Additional VTE chemoprophylaxis considerations that gained consensus were POD1 defined as the morning after surgery regardless of operating finishing time, enoxaparin as the medication of choice, and standardized, rather than weight-based, dose given once per day. Conclusions. In the first known Delphi study to address anticoagulation/antiplatelet recommendations for elective spine surgery (preoperatively and postoperatively); our Delphi consensus recommendations from 20 spine surgeons achieved consensus on 26/27 items. These results will potentially help standardize the management of preoperative AC/AP medication and VTE chemoprophylaxis after adult elective spine surgery.
BCKDK deficiency: a treatable neurodevelopmental disease amenable to newborn screening
Tangeraas, Trine , Constante, Juliana Ribeiro, Backe, Paul Hoff , Oyarzábal, Alfonso , Neugebauer, Julia , Weinhold, Natalie, Boemer, François , Debray, François Guillaume, Hişmi, Burcu Öztürk , Gümüş, Evren , Tuba, Eminoglu F, Öncül, Ümmühan , Footitt, Emma , Machado, Irene A., Al‐Sannaa, Nouriya , Santos, Mariela De Los, López, J. Muchart, Karaca, Meryem , Pajares, Sonia , Ormazábal, Aída , Stoway, Stephanie D., Artuch, Rafael , Dixon, Marjorie, Mørkrid, Lars , García‐Cazorla, Ángeles, Eminoğlu, Fatma Tuba , Constante, Juliana R , Davison, James E. , Martinez, Caroline, Bueno, Clarissa , Machado, Irene, Rodríguez‐Pombo, Pilar , Akay, Hatice , Tekin, Mustafa , García‐Cazorla, Àngels

Mayo Clinic

Brain | February 2, 2023 | Volume: 146 | Issue: 7 | Pages: 3003-3013

10.1093/brain/awad010 | PMID 36729635 Get It

Abstract There are few causes of treatable neurodevelopmental diseases described to date. Branched-chain ketoacid dehydrogenase kinase (BCKDK) deficiency causes branched-chain amino acid (BCAA) depletion and is linked to a neurodevelopmental disorder characterized by autism, intellectual disability and microcephaly. We report the largest cohort of patients studied, broadening the phenotypic and genotypic spectrum. Moreover, this is the first study to present newborn screening findings and mid-term clinical outcome. In this cross-sectional study, patients with a diagnosis of BCKDK deficiency were recruited via investigators’ practices through a MetabERN initiative. Clinical, biochemical and genetic data were collected. Dried blood spot (DBS) newborn screening (NBS) amino acid profiles were retrieved from collaborating centres and compared to a healthy newborn reference population. Twenty-one patients with BCKDK mutations were included from 13 families. Patients were diagnosed between 8 months and 16 years (mean: 5.8 years, 43% female). At diagnosis, BCAA levels (leucine, valine and isoleucine) were below reference values in plasma and in CSF. All patients had global neurodevelopmental delay; 18/21 had gross motor function (GMF) impairment with GMF III or worse in 5/18, 16/16 intellectual disability, 17/17 language impairment, 12/17 autism spectrum disorder, 9/21 epilepsy, 12/15 clumsiness, 3/21 had sensorineural hearing loss and 4/20 feeding difficulties. No microcephaly was observed at birth, but 17/20 developed microcephaly during follow-up. Regression was reported in six patients. Movement disorder was observed in 3/21 patients: hyperkinetic movements (1), truncal ataxia (1) and dystonia (2). After treatment with a high-protein diet (≥ 2 g/kg/day) and BCAA supplementation (100–250 mg/kg/day), plasma BCAA increased significantly (P &lt; 0.001), motor functions and head circumference stabilized/improved in 13/13 and in 11/15 patients, respectively. Among cases with follow-up data, none of the three patients starting treatment before 2 years of age developed autism at follow-up. The patient with the earliest age of treatment initiation (8 months) showed normal development at 3 years of age. NBS in DBS identified BCAA levels significantly lower than those of the normal population. This work highlights the potential benefits of dietetic treatment, in particular early introduction of BCAA. Therefore, it is of utmost importance to increase awareness about this treatable disease and consider it as a candidate for early detection by NBS programmes.
Evaluation of Soft-Tissue Hematomas With Real-Time, Contrast-Enhanced Ultrasound
Kummer, Tobias , Mohn, Kelli J., Bardwell, Abigail , Boyum, James H.

Mayo Clinic

Ultrasound Quarterly | February 2, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ruq.0000000000000621 | PMID 36731072 Get It

Abstract In this study, we investigated the feasibility of using contrast-enhanced ultrasound (CEUS) to detect active hemorrhage in patients presenting with soft-tissue hematomas. Adult patients with clinically suspected, actively bleeding hematomas were prospectively enrolled. Contrast-enhanced ultrasound was used to assess for contrast extravasation. Ultrasound results were compared with those of multidetector computed tomographic (MDCT) imaging, operative findings, and clinical course. Sixteen patients (9 women, 7 men; mean age, 69 [SD, 13] years) were enrolled. Thirteen patients underwent MDCT imaging during their initial visit, and for 11, CEUS and computed tomography (CT) findings were concordant. The remaining patients had a negative CEUS study that was consistent with their clinical course. In 8 patients, CT imaging showed active extravasation (6 arterial, 1 indeterminate, 1 slow venous). Contrast-enhanced ultrasound and CT findings were concordant for all cases of arterial bleeding. For 1 patient, CEUS provided superior diagnostic information by identifying a pseudoaneurysm. The 2 discrepant patient cases had a ≥3-hour delay between CT and CEUS, and in 1 patient, CEUS was limited by body habitus. The second patient had no active bleeding identified in the operating room. Compared with CT, CEUS had a sensitivity and specificity of 75% and 100%, respectively, and positive and negative predictive values were 100% and 71%, respectively. Diagnostic accuracy was 85% in this limited study. Contrast-enhanced ultrasound is a promising alternative to MDCT in select patients and may sometimes provide superior clinical information. Limiting factors are large hematoma size, unfavorable anatomic location, and body habitus.
The Effect of Free versus Local Flaps on Time to Union in Open Tibia Fractures
Zelenski, Nicole A. , Archual, Anthony J. , Bustos-Hemer, Samyd, Moran, Steven L. , Bustos, Samyd S. , Yan, María , Bustos, S S , Tangtiphaiboontana, Jennifer , Kuruoglu, Doga

Mayo Clinic

Plastic & Reconstructive Surgery | February 2, 2023 | Volume: 151 | Issue: 3 | Pages: 655-663

10.1097/prs.0000000000009934 | PMID 36730250 Get It

Background: Early soft-tissue reconstruction of open fractures has been shown to decrease infection rates and improve rates of bony union. The purpose of this study was to compare the rates and time to union of open tibia fractures that underwent soft-tissue coverage. Methods: A retrospective chart review of 118 patients with open tibia fractures requiring soft-tissue reconstruction treated at a single level 1 trauma center was performed. Demographic data as well as flap type were collected. Union status was determined using modified Radiographic Union Scale in Tibia Fractures score greater than 11. Results: Limb salvage was achieved in 90% of patients. The overall rate of nonunion was 33%. Flap type significantly affected time to union, with local fasciocutaneous and keystone flaps having significantly longer time to union [202 days (SD 120.3)] than all other flap groups (P = 0.01). Free flaps had significantly shorter time to union than local flaps [115 days (SD 49.6) versus 149 days (SD 75.4); P = 0.02]. Muscle flaps had significantly shorter time to union than fasciocutaneous flaps [123 days (SD 52.4) versus 165 days (SD 104.1); P = 0.04]. This remained true after controlling for fracture location, patient age, need for second flap, and fixation method (P = 0.037). Patients who underwent an initial soft-tissue reconstruction with a local muscle flap were more likely to require a second flap to achieve wound closure (OR, 3.7; P = 0.008) and needing a second flap significantly increased time to union [162 days (SD 95.9) versus 122 days (SD 51.9); P = 0.03]. Conclusion: Flap type affects time to union but not nonunion rate in open tibia fractures. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.
Capdevila, Jaume , Herrmann, Ken, Leyden, Simone , Mailman, Josh , Reidy‐Lagunes, Diane , Erdö, Máté, Rotger, Amanda, Thevenet, Thomas, Hálfdánarson, Þorvarður R. , Halperin, Daniel M. , Kong, Grace , Srirajaskanthan, Rajaventhan

Mayo Clinic

Journal of Clinical Oncology | February 2, 2023 | Volume: 41 | Issue: 4_suppl | Pages: TPS660-TPS660

10.1200/jco.2023.41.4_suppl.tps660 Get It

TPS660 Background: Deeper comprehension of gastroenteropancreatic neuroendocrine tumor (GEP-NET) characteristics has led to development of therapeutic interventions such as targeted radionuclide therapies (TRT). In the prospective, randomized, controlled, open-label, multi-center, Phase III COMPOSE trial, the radiolabeled somatostatin analogue 177Lu-edotreotide will be compared to approved standard of care with everolimus, CAPTEM or FOLFOX in patients with well-differentiated aggressive grade 2 and 3 (Ki-67 index 15−55%), somatostatin receptor positive GEP-NETS. While TRT is advantageous, a key unmet need is to identify additional markers intended to guide patient selection for TRT. This is highly relevant as TRT is a therapy of growing interest likely to be broadly available for patients with variable phenotypes. Profiling analysis as part of COMPOSE plans to analyze the genetic signature of GEP-NETS through full exome sequencing and gene expression analysis of tumor histology and longitudinal blood samples. This analysis may guide detection of pathogenic mutations in NET patients, to potentially inform treatment and surveillance strategies. Methods: Whole exome analysis of tumor-suppressor- and proto-oncogenes included in several pan-cancer panels, upstream and downstream regulators, and novel candidate genes, will be studied. Following patient consent, historical tumor biopsy and blood samples will undergo genetic analysis. Genetic profiling analysis inclusion will not impact trial involvement or disease management. DNA will be assessed to determine the impact of different types of mutations; mRNA will be assessed to confirm and quantify these assumptions and compare gene expression at different treatment phases. Samples will be analyzed in a central pathology laboratory. The aim of this analysis is to develop software that would integrate genetic data with structural and functional imaging, histopathology and phenotype information for implementation into clinical practice. Clinical trial information: NCT04919226 .